Capping a series of investments designed to boost its manufacturing footprint, Novo Nordisk has said it will spend around $550 million to increase output in Chi 20 March 2024
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
Mitsubishi Tanabe Pharma America has announced the publication of results in The Lancet Neurology from the pivotal, Phase III BouNDless trial. 18 March 2024
A new chief medical officer will take the reins at Shanghai-based biotech Everest Medicines, as the drug and vaccine firm undertakes a minor reshuffle at the to 18 March 2024
Japanese drugmaker Sumitomo Pharma and its American subsidiary Sumitomo Pharma America have amended a collaboration with Otsuka Pharmaceuticals. 18 March 2024
More than a year later than expected, Sino-American oncology specialist BeiGene has at last secured US approval for its novel checkpoint inhibitor, tislelizumab 15 March 2024
New real-world data show a positive safety profile for Xcopri (cenobamate), an anti-seizure medication which is offered in a tablet formulation. 14 March 2024
Politics has entered the scientific realm in the form of new US legislation that has prompted the Biotechnology Innovation Organization (BIO) to come into line 14 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.